Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

OBJECT: The objective of this double-blind, multicentre study was to evaluate four doses of sertindole and haloperidol 10 mg. METHOD: The 617 schizophrenic patients were randomized to receive sertindole 8, 16, 20 or 24 mg/day or haloperidol 10 mg/day. Patients were assessed for extrapyramidal symptoms (EPS) using the Simpson-Angus Scale (SAS) and Barnes Akathisia Scale (BAS), and for movement disorders using the Abnormal Involuntary Movement Scale (AIMS). RESULTS: Patients receiving haloperidol experienced significantly more EPS than patients receiving sertindole, supporting observations made in previous studies. The incidence of adverse events was similar for all doses of sertindole. SAS and BAS scores were significantly worse in the haloperidol group than in the sertindole groups. There were significantly greater increases in mean QT c interval in the sertindole groups than in the haloperidol group. Sertindole did not cause sedation. CONCLUSIONS: Sertindole is well tolerated and does not cause the debil...

[1]  W. Maier,et al.  Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial , 2000 .

[2]  S. Kasper,et al.  Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[3]  D. Fogelson,et al.  A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. , 1997, Journal of clinical psychopharmacology.

[4]  P. Weiden,et al.  Switching antipsychotic medications. , 1997, The Journal of clinical psychiatry.

[5]  C. Stilwell,et al.  P.2.081 Extrapyramidal symptoms and sertindole — analysis of three double-blind, haloperidol-referenced, phase III clinical trials , 1997, European Neuropsychopharmacology.

[6]  C. Tamminga,et al.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. , 1997, The American journal of psychiatry.

[7]  C. Tamminga,et al.  Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety , 1997, International clinical psychopharmacology.

[8]  C. Halldin,et al.  Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs , 1996, British Journal of Psychiatry.

[9]  S. Schulz,et al.  Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients , 1996, Schizophrenia Research.

[10]  N. Andreasen,et al.  Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation , 1995, Biological Psychiatry.

[11]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[12]  R. Poland,et al.  Haloperidol plasma levels and clinical response: a therapeutic window relationship. , 1992, The American journal of psychiatry.

[13]  J. Lieberman,et al.  Prospective study of tardive dyskinesia incidence in the elderly. , 1991, JAMA.

[14]  Daniel E. Casey,et al.  Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia , 1991, Schizophrenia Research.

[15]  C. Sánchez,et al.  Neurochemical and in vivo pharmacological profile of sertindole, a limbic‐selective neuroleptic compound , 1991 .

[16]  J. Perregaard,et al.  Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. , 1990, European journal of pharmacology.

[17]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[18]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[19]  G. Keepers,et al.  Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. , 1988, Psychopharmacology series.

[20]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.